A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines

NCT01949675 | Completed Phase 4

• 2 other identifiers: SHC02U1111-1127-7355
• Study Type: interventional
• Target: 336
• Locations: 1 country
• Sites: 2

Brief Summary

The aim of the study is to generate safety and immunogenicity data with Oral Cholera Vaccine (Shanchol™) in The Philippines Objectives:

• To describe the safety after each dose of Shanchol vaccine.
• To describe the immunogenicity after each dose of Shanchol vaccine.

Conditions

Cholera

Keywords

Cholera; Shanchol™; Cholera Vaccine

Outcome Measures

Primary Outcomes (2)

• Number of participants reporting unsolicited systemic adverse events; solicited systemic reactions including serious adverse events following administration Oral Cholera Vaccine (Shanchol™)

  Solicited systemic reaction: Vomiting, Diarrhea, Fever (temperature), Abdominal pain, Itching, Rash, Weakness, Cough, Vertigo, and Dryness of Mouth

  Day 0 up to Day 44 post oral vaccination

• Summary of titers of serum vibriocidal antibodies Before and 14 days after each Oral Cholera Vaccine (Shanchol™)

  Serum vibriocidal antibody (against V. cholerae O1 Inaba serogroup, V. cholerae O1 Ogawa serogroup, and V. cholerae O139 serogroup) will be assessed using the microtiter technique.

  Day 0 (before) and Day 14 post oral vaccination

Secondary Outcomes (1)

• Number of participants with 4-fold or greater rises in titers 14 days after each Oral Cholera Vaccine (Shanchol™) relative to baseline

  Day 0 (before) and Day 14 post oral vaccination

Study Arms (3)

Study Group 1

EXPERIMENTAL

Participants aged 1 through 4 years at enrollment

Biological: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell

Study Group 2

EXPERIMENTAL

Participants aged 5 through 14 years at enrollment

Biological: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell

Study Group 3

EXPERIMENTAL

Participants aged 15 years and above at enrollment

Biological: Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell

Interventions

Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell BIOLOGICAL

1.5 mL, Oral administration

Also known as: Shanchol™

Study Group 1

Eligibility Criteria

• Age: 1 Year+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects aged 1 through 17 years: informed consent form has been signed and dated by the subject's parent (and subject, if applicable by local Institution Ethics Committee (IEC) / Institution Review Board (IRB) or country regulations), or another legally acceptable representative (and independent witness, if required by local regulations), and the assent form has been signed and dated by the subject (if applicable by the local IEC / IRB or country regulations)
• Subjects aged 18 years and older: informed consent form has been signed and dated by the subject (and an independent witness, if required by local regulations).
• Subject and subject's parent / legally acceptable representative (if applicable) are able to attend all scheduled visits and to comply with all trial procedures
• Subjects aged less than 2 years only: Born at full term of pregnancy (≥ 37 weeks) and/or with a birth weight ≥ 2.5 kg.

You may not qualify if:

• Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche or post-menopausal for at least 1 year, surgically sterile, or using an effective method of contraception or abstinence from at least 4 weeks prior to the first vaccination and until at least 4 weeks after the last vaccination)
• Participation at the time of study enrollment or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure
• Receipt of any vaccine in the 4 weeks preceding the first trial vaccination or planned receipt of any vaccine in the 4 weeks following any trial vaccination except for influenza vaccination, which may be received at least 2 weeks before or after any study vaccination
• Previous vaccination against cholera (in the previous 5 years) with either the trial vaccine or another vaccine
• Receipt of immune globulins, blood or blood-derived products in the past 3 months
• Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
• History of cholera infection, confirmed either clinically, serologically, or microbiologically
• At high risk for cholera infection during the trial (i.e., cholera outbreak situation or close contact to cholera case)
• Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances
• Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
• Current alcohol abuse or drug addiction
• Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion
• Intake of oral antibiotics within one week prior to enrollment
• Moderate or severe acute illness/infection (according to investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided
• Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural, or adopted child) of the Investigator or employee with direct involvement in the proposed study

Sponsors & Collaborators

• Sanofi Pasteur, a Sanofi Company: lead

Study Sites (2)

Unknown Facility

City of Muntinlupa, Philippines

Location

Unknown Facility

Manila, Philippines

Location

Related Publications (1)

• Capeding MRZ, Gonzales MLAM, Dhingra MS, D'Cor NA, Midde VJ, Patnaik BN, Thollot Y, Desauziers E. Safety and immunogenicity of the killed bivalent (O1 and O139) whole-cell cholera vaccine in the Philippines. Hum Vaccin Immunother. 2017 Oct 3;13(10):2232-2239. doi: 10.1080/21645515.2017.1342908.

  PMID: 28910563 RESULT

MeSH Terms

Conditions

Cholera

Interventions

shanchol

Condition Hierarchy (Ancestors)

Vibrio Infections; Gram-Negative Bacterial Infections; Bacterial Infections; Bacterial Infections and Mycoses; Infections

Study Officials

• Medical Director

  Sanofi Pasteur SA

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 20, 2013
• First Posted: September 24, 2013
• Study Start: March 1, 2014
• Primary Completion: February 1, 2015
• Study Completion: August 1, 2015
• Last Updated: March 23, 2018

Record last verified: 2018-03

Locations

PH (2)